Advanced breast cancer drugs was approved by SFDA

AstraZeneca announced that Fulvestrant Injection, 250mg dosage has been approved by SFDA in china. The drugs have been used in the treatment of advanced breast cancer. It cancontrol and prevent breast cancer recurrence and metastasis efficiently. Breast cancer is the most common cancer in women. It is the most common major cancer in American women. Although surgery is the primary therapy for the treatment of advanced breast cancer, it is notsuitable for all breast cancer patients, particularly in elderly patients. The cancer patients can accept endocrine therapy, The cancer patients can accept endocrine therapy, Anti-estrogen drugs to inhibit cancer cell growth and kill some cancer cells. Anti-estrogen drugs such as tamoxifen (Novaldex) are a standard treatment for hormone-dependent breast cancer. Between 10 and 20 percent of breast cancers are advanced or hae already started to spread at the time they are diagnosed. Fulvestrant injection is used to prevent recurrence or metastasis during the anti-estrogen therapy. Fulvestrant Injection is a self-help development by the AstraZeneca. It is a new endocrinetherapy in breast cancer. It is a new estrogen receptor antagonist. include the excitant or antagonist of gastrin receptor. It received marketing approval in more than 70 countries / regions. more anti-cancer foods such as Soybean: The soybean contains the isoflavone richly, it is planter natural estrogen, simultaneously also has the oxidation resistance ability.